E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Elias Jabbour,Hagop M. Kantarjian,Dan Jones,Megan Breeden,Guillermo Garcia-Manero,Susan O'Brien,Farhad Ravandi,Gautam Borthakur,Jorge E. Cortes +8 more
TL;DR: Except for the lack of response to second TKIs (P = .002), there was no difference in patient characteristics and outcome between patients with T315I and those with other or no mutations.
Journal ArticleDOI
Chromosomal abnormalities in Philadelphia chromosome–negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Elias Jabbour,Hagop M. Kantarjian,Lynne V. Abruzzo,Susan O'Brien,Guillermo Garcia-Manero,Srdan Verstovsek,Jianqin Shan,Mary Beth Rios,Jorge E. Cortes +8 more
TL;DR: CAs occur in Ph-negative cells in a small percentage of patients with newly diagnosed CML treated with IM, and in rare instances, these could reflect the emergence of a new malignant clone.
Journal ArticleDOI
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Guillermo Garcia-Manero,Pierre Fenaux,Aref Al-Kali,Maria R. Baer,Mikkael A. Sekeres,Gail J. Roboz,Gianluca Gaidano,Bart L. Scott,Peter L. Greenberg,Uwe Platzbecker,David P. Steensma,Suman Kambhampati,Karl Anton Kreuzer,Lucy A. Godley,Ehab Atallah,Robert H. Collins,Hagop M. Kantarjian,Elias Jabbour,Francois Wilhelm,Nozar Azarnia,Lewis R. Silverman +20 more
TL;DR: Overall survival was compared with best supportive care only in patients with myelodysplastic syndromes with excess blasts after failure of azacitidine or decitabine treatment and Rigosertib did not significantly improve overall survival.
Journal ArticleDOI
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Courtney D. DiNardo,Curtis Lachowiez,Koichi Takahashi,Sanam Loghavi,Lianchun Xiao,Tapan M. Kadia,Naval Daver,Maria Adeoti,Nicholas J. Short,Koji Sasaki,Sa Wang,Gautam Borthakur,Ghayas C. Issa,Abhishek Maiti,Yesid Alvarado,Naveen Pemmaraju,Guillermo Montalban Bravo,Lucia Masarova,Musa Yilmaz,Nitin Jain,Michael Andreeff,Elias Jabbour,Guillermo Garcia-Manero,Steven M. Kornblau,Farhad Ravandi,Marina Konopleva,Hagop M. Kantarjian +26 more
TL;DR: The authors showed that 60% of newly diagnosed patients with acute myeloid leukemia (ND-AML) receiving frontline therapy attain complete response (CR) yet 30%-40% of patients relapse.
Journal ArticleDOI
Monoclonal antibodies in acute lymphoblastic leukemia
TL;DR: Combined modalities of chemotherapy and the novel monoclonal antibodies are under investigation and there is a need to develop effective salvage therapies and combine novel agents with standard effective chemotherapy.